Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33814336/
Despite improvements in therapy, approximately 5% of patients who undergo autologous stem cell transplantation (ASCT) experience early mortality (EM), death within 1 year of transplant (EM post-ASCT). Such patients tend...
-
Mark Fesler4yrDeath within a year of autoSCT not only indicates a disease resistant to chemo but also novel agents given the prolonged pfs of triplet regimens in salvage. These patients Show More
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33682447/
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates...
-
Mark Fesler4yrThis antibody conjugate has intriguing efficacy in a population of patients that has few options ...
Antibody-Based Treatment Approaches in Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33730360/
Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment...
-
Mark Fesler4yrThere are many more surface targets that have been identified in myeloma beyond cd38, slamf1, and bcma which is extremely exciting for the future of myeloma care
Autologous hematopoietic transplantation following COVID‐19 infection
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981617/
Marthilde Brzycki, 1 Robert Richard, 1 , 2 Nicholas Burwick, 1 , 2 Solomon Graf, 1 , 3 , 4 Craig O'Brien, 1 Daniel Wu, 1 , 3 and Thomas...
-
Mark Fesler4yrAn interesting report. More knowledge in this area is needed as clinicians presently face challenging decisions on balancing risks of malignancy and covid without a solid evidence base
FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult...
-
Mark Fesler4yrAn expanded indication for a cd38 antibody, which are in key class of medications in the treatment of myeloma ...